Tumor–stromal interactions in lung cancer: novel candidate targets for therapeutic intervention

Bibliography

• Langer CJ, Besse B, Gualberto A, The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 2010;28:5311-20
   PubMed Web of Science ®Google Scholar
• Lee G, Walser TC, Dubinett SM. Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer. Curr Opin Pulm Med 2009;15:303-7
   PubMed Web of Science ®Google Scholar
• Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 2010;316:1324-31
   PubMed Web of Science ®Google Scholar
• Shaked Y, Voest EE. Bone marrow derived cells in tumor angiogenesis and growth: are they the good, the bad or the evil? Biochim Biophys Acta 2009;1796:1-4
   PubMed Web of Science ®Google Scholar
• Sautes-Fridman C, Cherfils-Vicini J, Damotte D, Tumor microenvironment is multifaceted. Cancer Metastasis Rev 2011;30:13-25
   PubMed Web of Science ®Google Scholar
• Saffiotti U, Daniel LN, Mao Y, Mechanisms of carcinogenesis by crystalline silica in relation to oxygen radicals. Environ Health Perspect 1994;102(Suppl 10):159-63
   PubMed Web of Science ®Google Scholar
• Coggins CR. A further review of inhalation studies with cigarette smoke and lung cancer in experimental animals, including transgenic mice. Inhal Toxicol 2010;22:974-83
   PubMed Web of Science ®Google Scholar
• Bremnes RM, Donnem T, Al-Saad S, The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol 2011;6:209-17
   PubMed Web of Science ®Google Scholar
• Navab R, Strumpf D, Bandarchi B, Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc Natl Acad Sci USA 2011;108:7160-5
   PubMed Web of Science ®Google Scholar
• Langley RR, Fidler IJ. The seed and soil hypothesis revisited–the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 2011;128:2527-35
   PubMed Web of Science ®Google Scholar
• Kaplan RN, Riba RD, Zacharoulis S, VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438:820-7
   PubMed Web of Science ®Google Scholar
• Okahara H, Yagita H, Miyake K, Okumura K. Involvement of very late activation antigen 4 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) in tumor necrosis factor alpha enhancement of experimental metastasis. Cancer Res 1994;54:3233-6
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
   PubMed Web of Science ®Google Scholar
• Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-74
   PubMed Web of Science ®Google Scholar
• Wilmanns C, Fan D, O'Brian CA, Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. Int J Cancer 1992;52:98-104
   PubMed Web of Science ®Google Scholar
• Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4:839-49
   PubMed Web of Science ®Google Scholar
• Ostman A, Augsten M. Cancer-associated fibroblasts and tumor growth–bystanders turning into key players. Curr Opin Genet Dev 2009;19:67-73
   PubMed Web of Science ®Google Scholar
• Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004;432:332-7
   PubMed Web of Science ®Google Scholar
• Massague J. TGFbeta in Cancer. Cell 2008;134:215-30
   PubMed Web of Science ®Google Scholar
• Mazzocca A, Fransvea E, Dituri F, Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. Hepatology 2010;51:523-34
   PubMed Web of Science ®Google Scholar
• Wang W, Li Q, Yamada T, Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 2009;15:6630-8
   PubMed Web of Science ®Google Scholar
• Donnem T, Al-Saad S, Al-Shibli K, Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells. J Thorac Oncol 2008;3:963-70
   PubMed Web of Science ®Google Scholar
• Kryczek I, Wei S, Keller E, Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol 2007;292:C987-95
   PubMed Web of Science ®Google Scholar
• Otsuka S, Bebb G. The CXCR4/SDF-1 chemokine receptor axis: a new target therapeutic for non-small cell lung cancer. J Thorac Oncol 2008;3:1379-83
   PubMed Web of Science ®Google Scholar
• Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009;9:239-52
   PubMed Web of Science ®Google Scholar
• Valtieri M, Sorrentino A. The mesenchymal stromal cell contribution to homeostasis. J Cell Physiol 2008;217:296-300
   PubMed Web of Science ®Google Scholar
• Pittenger MF, Mackay AM, Beck SC, Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-7
   PubMed Web of Science ®Google Scholar
• Bergfeld SA, DeClerck YA. Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev 2010;29:249-61
   PubMed Web of Science ®Google Scholar
• Son BR, Marquez-Curtis LA, Kucia M, Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells 2006;24:1254-64
   PubMed Web of Science ®Google Scholar
• Rajantie I, Ilmonen M, Alminaite A, Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 2004;104:2084-6
   PubMed Web of Science ®Google Scholar
• Noel D, Djouad F, Bouffi C, Multipotent mesenchymal stromal cells and immune tolerance. Leuk Lymphoma 2007;48:1283-9
   PubMed Web of Science ®Google Scholar
• Karnoub AE, Dash AB, Vo AP, Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557-63
   PubMed Web of Science ®Google Scholar
• Martin FT, Dwyer RM, Kelly J, Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res Treat 2010;124:317-26
   PubMed Web of Science ®Google Scholar
• Qiao L, Xu ZL, Zhao TJ, Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Lett 2008;269:67-77
   PubMed Web of Science ®Google Scholar
• Khakoo AY, Pati S, Anderson SA, Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 2006;203:1235-47
   PubMed Web of Science ®Google Scholar
• Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-8
   PubMed Web of Science ®Google Scholar
• Welsh TJ, Green RH, Richardson D, Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 2005;23:8959-67
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sica A, Locati M. New vistas on macrophage differentiation and activation. Eur J Immunol 2007;37:14-16
   PubMed Web of Science ®Google Scholar
• Sanchez-Martin L, Estecha A, Samaniego R, The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. Blood 2011;117:88-97
   PubMed Web of Science ®Google Scholar
• Hallam S, Escorcio-Correia M, Soper R, Activated macrophages in the tumour microenvironment-dancing to the tune of TLR and NF-kappaB. J Pathol 2009;219:143-52
   PubMed Web of Science ®Google Scholar
• Schmidt T, Ben-Batalla I, Schultze A, Loges S. Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands. Cell Mol Life Sci 2012;69:1391-414
   PubMed Web of Science ®Google Scholar
• Ma J, Liu L, Che G, The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 2010;10:112
   PubMed Web of Science ®Google Scholar
• Bennaceur K, Chapman JA, Touraine JL, Portoukalian J. Immunosuppressive networks in the tumour environment and their effect in dendritic cells. Biochim Biophys Acta 2009;1795:16-24
   PubMed Web of Science ®Google Scholar
• Taylor A, Verhagen J, Blaser K, Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology 2006;117:433-42
   PubMed Web of Science ®Google Scholar
• Harding FA, McArthur JG, Gross JA, CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992;356:607-9
   PubMed Web of Science ®Google Scholar
• Bennaceur K, Popa I, Portoukalian J, Melanoma-derived gangliosides impair migratory and antigen-presenting function of human epidermal Langerhans cells and induce their apoptosis. Int Immunol 2006;18:879-86
   PubMed Web of Science ®Google Scholar
• Wesa AK, Storkus WJ. Killer dendritic cells: mechanisms of action and therapeutic implications for cancer. Cell Death Differ 2008;15:51-7
   Google Scholar
• Ladanyi A, Kiss J, Somlai B, Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 2007;56:1459-69
   PubMed Web of Science ®Google Scholar
• Perrot I, Blanchard D, Freymond N, Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol 2007;178:2763-9
   PubMed Web of Science ®Google Scholar
• Ye XZ, Yu SC, Bian XW. Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis. J Genet Genomics 2010;37:423-30
   Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74
   PubMed Web of Science ®Google Scholar
• Sinha P, Clements VK, Bunt SK, Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007;179:977-83
   PubMed Web of Science ®Google Scholar
• Kusmartsev S, Gabrilovich DI. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol 2005;174:4880-91
   PubMed Web of Science ®Google Scholar
• Ray P, Arora M, Poe SL, Ray A. Lung myeloid-derived suppressor cells and regulation of inflammation. Immunol Res 2011;50:153-8
   PubMed Web of Science ®Google Scholar
• Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 2006;8:1369-75
   PubMed Web of Science ®Google Scholar
• Huysentruyt LC, Mukherjee P, Banerjee D, Metastatic cancer cells with macrophage properties: evidence from a new murine tumor model. Int J Cancer 2008;123:73-84
   PubMed Web of Science ®Google Scholar
• Fridlender ZG, Sun J, Kim S, Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell 2009;16:183-94
   PubMed Web of Science ®Google Scholar
• Piccard H, Muschel RJ, Opdenakker G. On the dual roles and polarized phenotypes of neutrophils in tumor development and progression. Crit Rev Oncol Hematol 2012;82:296-309
   PubMed Web of Science ®Google Scholar
• Daley JM, Thomay AA, Connolly MD, Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J Leukoc Biol 2008;83:64-70
   PubMed Web of Science ®Google Scholar
• Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol 2005;6:135-42
   PubMed Web of Science ®Google Scholar
• Ibaraki T, Muramatsu M, Takai S, The relationship of tryptase- and chymase-positive mast cells to angiogenesis in stage I non-small cell lung cancer. Eur J Cardiothorac Surg 2005;28:617-21
   PubMed Web of Science ®Google Scholar
• Carlini MJ, Dalurzo MC, Lastiri JM, Mast cell phenotypes and microvessels in non-small cell lung cancer and its prognostic significance. Hum Pathol 2010;41:697-705
   PubMed Web of Science ®Google Scholar
• Yoshii M, Jikuhara A, Mori S, Mast cell tryptase stimulates DLD-1 carcinoma through prostaglandin- and MAP kinase-dependent manners. J Pharmacol Sci 2005;98:450-8
   PubMed Web of Science ®Google Scholar
• Norrby K. Mast cells and angiogenesis. APMIS 2002;110:355-71
   PubMed Web of Science ®Google Scholar
• Barnas JL, Simpson-Abelson MR, Yokota SJ, T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets. Cancer Microenviron 2010;3:29-47
   PubMedGoogle Scholar
• Taniguchi M, Tashiro T, Dashtsoodol N, The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy. Int Immunol 2010;22:1-6
   Google Scholar
• Smyth MJ, Godfrey DI. NKT cells and tumor immunity–a double-edged sword. Nat Immunol 2000;1:459-60
   PubMed Web of Science ®Google Scholar
• Konishi J, Yamazaki K, Yokouchi H, The characteristics of human NKT cells in lung cancer–CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients. Hum Immunol 2004;65:1377-88
   PubMed Web of Science ®Google Scholar
• Rijavec M, Volarevic S, Osolnik K, Natural killer T cells in pulmonary disorders. Respir Med 2011;105(Suppl 1):S20-5
   PubMedGoogle Scholar
• Rettig WJ, Garin-Chesa P, Healey JH, Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res 1993;53:3327-35
   PubMed Web of Science ®Google Scholar
• Scott AM, Wiseman G, Welt S, A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 2003;9:1639-47
   PubMed Web of Science ®Google Scholar
• Hofheinz RD, al-Batran SE, Hartmann F, Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie 2003;26:44-8
   PubMedGoogle Scholar
• Cheng JD, Dunbrack RL Jr, Valianou M, Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res 2002;62:4767-72
   PubMed Web of Science ®Google Scholar
• Rasanen K, Vaheri A. Activation of fibroblasts in cancer stroma. Exp Cell Res 2010;316:2713-22
   PubMed Web of Science ®Google Scholar
• Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309
   PubMed Web of Science ®Google Scholar
• Socinski MA. Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer. Cancer Treat Rev 2011;37:611-17
   PubMed Web of Science ®Google Scholar
• Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10:9-22
   PubMed Web of Science ®Google Scholar
• Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer 2004;90:561-5
   PubMed Web of Science ®Google Scholar
• Almokadem S, Belani CP. Volociximab in cancer. Expert Opin Biol Ther 2012;12:251-7
   PubMed Web of Science ®Google Scholar
• Hua H, Li M, Luo T, Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci 2011;68:3853-68
   PubMed Web of Science ®Google Scholar
• Rosen PJ, Sweeney CJ, Park DJ, A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clin Cancer Res 2010;16:2677-87
   PubMed Web of Science ®Google Scholar
• Arteaga CL. Inhibition of TGFbeta signaling in cancer therapy. Curr Opin Genet Dev 2006;16:30-7
   PubMed Web of Science ®Google Scholar
• Burger JA, Stewart DJ, Wald O, Peled A. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Rev Anticancer Ther 2011;11:621-30
   PubMed Web of Science ®Google Scholar
• Gangadhar T, Nandi S, Salgia R. The role of chemokine receptor CXCR4 in lung cancer. Cancer Biol Ther 2010;9:409-16
   PubMedGoogle Scholar
• Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009;23:43-52
   PubMed Web of Science ®Google Scholar
• Fulciniti M, Hideshima T, Vermot-Desroches C, A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res 2009;15:7144-52
   PubMed Web of Science ®Google Scholar
• Ren C, Kumar S, Chanda D, Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells 2008;26:2332-8
   PubMed Web of Science ®Google Scholar
• Kidd S, Caldwell L, Dietrich M, Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy 2010;12:615-25
   PubMed Web of Science ®Google Scholar
• Chen X, Lin X, Zhao J, A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Mol Ther 2008;16:749-56
   PubMed Web of Science ®Google Scholar
• Kanehira M, Xin H, Hoshino K, Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells. Cancer Gene Ther 2007;14:894-903
   PubMed Web of Science ®Google Scholar
• Loebinger MR, Eddaoudi A, Davies D, Janes SM. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 2009;69:4134-42
   PubMed Web of Science ®Google Scholar
• Kim SM, Lim JY, Park SI, Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 2008;68:9614-23
   PubMed Web of Science ®Google Scholar
• Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002;196:254-65
   PubMed Web of Science ®Google Scholar
• Fridlender ZG, Kapoor V, Buchlis G, Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells. Am J Respir Cell Mol Biol 2011;44:230-7
   Google Scholar
• Fridlender ZG, Buchlis G, Kapoor V, CCL2 blockade augments cancer immunotherapy. Cancer Res 2010;70:109-18
   Google Scholar
• Gamez-Pozo A, Sanchez-Navarro I, Calvo E, PTRF/Cavin-1 and MIF Proteins Are Identified as Non-Small Cell Lung Cancer Biomarkers by Label-Free Proteomics. PLoS ONE 2012;7:e33752
   PubMedGoogle Scholar
• Winner M, Meier J, Zierow S, A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells. Cancer Res 2008;68:7253-7
   PubMed Web of Science ®Google Scholar
• Ito M, Ishii G, Nagai K, Prognostic impact of cancer-associated stromal cells in stage I lung adenocarcinoma patients. Chest 2012
   Google Scholar
• Perroud MW Jr, Honma HN, Barbeiro AS, Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study. J Exp Clin Cancer Res 2011;30:65
   PubMed Web of Science ®Google Scholar
• O'Mahony D, Kummar S, Gutierrez ME. Non-small-cell lung cancer vaccine therapy: a concise review. J Clin Oncol 2005;23:9022-8
   PubMed Web of Science ®Google Scholar
• Chiappori AA, Soliman H, Janssen WE, INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther 2010;10:983-91
   PubMed Web of Science ®Google Scholar
• Morse MA, Clay TM, Hobeika AC, Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res 2005;11:3017-24
   PubMed Web of Science ®Google Scholar
• Hengesbach LM, Hoag KA. Physiological concentrations of retinoic acid favor myeloid dendritic cell development over granulocyte development in cultures of bone marrow cells from mice. J Nutr 2004;134:2653-9
   PubMed Web of Science ®Google Scholar
• Nefedova Y, Fishman M, Sherman S, Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res 2007;67:11021-8
   PubMed Web of Science ®Google Scholar
• Lathers DM, Clark JI, Achille NJ, Young MR. Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunol Immunother 2004;53:422-30
   PubMed Web of Science ®Google Scholar
• Nefedova Y, Nagaraj S, Rosenbauer A, Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res 2005;65:9525-35
   PubMed Web of Science ®Google Scholar
• Ko JS, Zea AH, Rini BI, Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009;15:2148-57
   PubMed Web of Science ®Google Scholar
• Ugel S, Delpozzo F, Desantis G, Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol 2009;9:470-81
   PubMed Web of Science ®Google Scholar
• Macgregor JN, Li Q, Chang AE, Ex vivo culture with interleukin (IL)-12 improves CD8(+) T-cell adoptive immunotherapy for murine leukemia independent of IL-18 or IFN-gamma but requires perforin. Cancer Res 2006;66:4913-21
   Google Scholar
• Zou JP, Yamamoto N, Fujii T, Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int Immunol 1995;7:1135-45
   PubMed Web of Science ®Google Scholar
• Sugiyama Y, Kato M, Chen FA, Human inflammatory cells within the tumor microenvironment of lung tumor xenografts mediate tumor growth suppression in situ that depends on and is augmented by interleukin-12. J Immunother 2001;24:37-45
   PubMed Web of Science ®Google Scholar
• Motohashi S, Okamoto Y, Yoshino I, Nakayama T. Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer. Clin Immunol 2011;140:167-76
   PubMed Web of Science ®Google Scholar
• Motohashi S, Nagato K, Kunii N, A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 2009;182:2492-501
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Ishii G, Taira T, Fibrous stroma is associated with poorer prognosis in lung squamous cell carcinoma patients. J Thorac Oncol 2011;6:1460-7
   PubMed Web of Science ®Google Scholar
• Nakao M, Ishii G, Nagai K, Prognostic significance of carbonic anhydrase IX expression by cancer-associated fibroblasts in lung adenocarcinoma. Cancer 2009;115:2732-43
   PubMed Web of Science ®Google Scholar
• Ishikawa S, Takenaka K, Yanagihara K, Matrix metalloproteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small-cell lung cancer. Clin Cancer Res 2004;10:6579-85
   PubMed Web of Science ®Google Scholar
• Donnem T, Al-Shibli K, Al-Saad S, Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival. J Thorac Oncol 2009;4:578-85
   PubMed Web of Science ®Google Scholar
• Hiraoka K, Miyamoto M, Cho Y, Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006;94:275-80
   PubMed Web of Science ®Google Scholar
• Ruffini E, Asioli S, Filosso PL, Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg 2009;87:365-71; discussion 371-362
   Google Scholar
• Wakabayashi O, Yamazaki K, Oizumi S, CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci 2003;94:1003-9
   PubMed Web of Science ®Google Scholar
• Al-Shibli KI, Donnem T, Al-Saad S, Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008;14:5220-7
   PubMed Web of Science ®Google Scholar
• Pages F, Galon J, Dieu-Nosjean MC, Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010;29:1093-102
   PubMed Web of Science ®Google Scholar
• Petersen RP, Campa MJ, Sperlazza J, Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006;107:2866-72
   PubMed Web of Science ®Google Scholar
• Shimizu K, Nakata M, Hirami Y, Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 2010;5:585-90
   PubMed Web of Science ®Google Scholar
• Liu CY, Wang YM, Wang CL, Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 2010;136:35-45
   PubMed Web of Science ®Google Scholar
• Chen JJ, Yao PL, Yuan A, Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res 2003;9:729-37
   PubMed Web of Science ®Google Scholar
• Ho CC, Liao WY, Wang CY, TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. Am J Respir Crit Care Med 2008;177:763-70
   PubMed Web of Science ®Google Scholar
• Suzuki K, Kachala SS, Kadota K, Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res 2011;17:5247-56
   Google Scholar